Sagent Pharmaceuticals

Sagent Pharmaceuticals is focused on developing, manufacturing, sourcing and marketing pharmaceutical products. The Company offers its customers a broad range of products across anti-infective, oncology and critical care indications in a variety of presentations, including single- and multi-dose vials and ready-to-use pre-filled syringes and premix bags. Sagent generally seeks to develop injectable products where the form or packaging of the product can be enhanced to improve delivery, product safety or end-user convenience.

Type
Subsidiary
HQ
Schaumburg, US
Founded
2006
Sagent Pharmaceuticals was founded in 2006 and is headquartered in Schaumburg, US

Sagent Pharmaceuticals Office Locations

Sagent Pharmaceuticals has an office in Schaumburg
Schaumburg, US (HQ)
1901 N. Roselle Road

Sagent Pharmaceuticals Data and Metrics

Sagent Pharmaceuticals Summary

Founding Date

2006

Total Funding

$70 m

Investors

Sagent Pharmaceuticals Financial Metrics

Sagent Pharmaceuticals's revenue was reported to be $318.3 m in FY, 2015 which is a 10% increase from the previous period.
USDFY, 2013FY, 2014FY, 2015

Revenue

244.8 m289 m318.3 m

Revenue growth, %

18%10%

Cost of goods sold

167.2 m202.8 m230.6 m

Gross profit

77.5 m86.2 m87.7 m

Gross profit Margin, %

32%30%28%

Operating expense total

54.1 m67.1 m84.7 m

EBIT

29 m15.1 m(47.1 m)

EBIT margin, %

12%5%(15%)

Interest expense

(930 k)(2.2 m)(770 k)

Pre tax profit

30.5 m16.2 m(48.1 m)

Income tax expense

895 k(23.7 m)(26.2 m)

Net Income

29.6 m39.9 m(21.9 m)
USDFY, 2013FY, 2014FY, 2015

Cash

42.3 m55.6 m29 m

Inventories

6.5 m5.6 m7.4 m

Current Assets

235.8 m198.5 m191.6 m

PP&E

57.7 m71.2 m19.8 m

Goodwill

6 m28.2 m25.2 m

Total Assets

310.2 m381.5 m349.7 m

Accounts Payable

24.9 m32.7 m43.7 m

Total Debt

8 m

Current Liabilities

63.5 m85.6 m83.7 m

Additional Paid-in Capital

349.3 m353 m367.2 m

Retained Earnings

(114.1 m)(74.2 m)(99 m)

Total Equity

236 m275.8 m251.1 m

Debt to Equity Ratio

0 x

Debt to Assets Ratio

0 x

Financial Leverage

1.3 x1.4 x1.4 x
USDFY, 2013FY, 2014FY, 2015

Net Income

29.6 m39.9 m(21.9 m)

Depreciation and Amortization

7.1 m9.5 m13.7 m

Accounts Receivable

8.6 m(16 m)(9.3 m)

Inventories

(3.5 m)2.2 m(2.6 m)

Cash From Operating Activities

49.6 m23.2 m(7.5 m)

Capital Expenditures

(1.1 m)(4.2 m)(6.7 m)

Cash From Investing Activities

(97.2 m)(932 k)(22 m)

Long-term Borrowings

(9 m)(10.4 m)(471 k)

Cash From Financing Activities

62.3 m(8.5 m)3.5 m

Interest Paid

652 k1.4 m414 k

Income Taxes Paid

2.6 m4.3 m

Free Cash Flow

50.7 m27.4 m(812 k)

Traffic Overview of Sagent Pharmaceuticals

Sagent Pharmaceuticals News and Updates

Teva Is Approved to Purchase Allergan’s Generics Business

The pharmaceutical company won antitrust approval after agreeing to sell rights and assets related to 79 generic drugs to rival firms.

BRIEF-Japan's Nichi-Iko to buy Sagent Pharmaceuticals for $21.75 per share in cash

* Nichi-Iko pharmaceutical Co, Ltd to acquire Sagent Pharmaceuticals for $21.75 per share in all cash transaction

Mayne Pharma nears deal for Teva assets: source

(Reuters) - Australia's Mayne Pharma Group Ltd on Tuesday said it will acquire U.S. generic products from Teva Pharmaceuticals for $652 million, helping it propel into the top 2 in the general oral contraceptives market in the United States.

UPDATE 1-Mayne Pharma nears deal for Teva assets -source

June 27 (Reuters) - Australia's Mayne Pharma Group Ltd on Tuesday said it will acquire U.S. generic products from Teva Pharmaceuticals for $652 million, helping it propel into the top 2 in the general oral contraceptives market in the United States.

Sagent Pharmaceuticals Company Life and Culture

You may also be interested in